Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard and high risk myeloma
|Study ID||Alternative Stable ID||Type|
Study Datasets 1 dataset.
Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data
WES data from clonal pahtologic bone marrow plasma cells of multiple myeloma patients. From each patient there are three samples, pathologyc bone marrow plasma cells at diagnosis, pathologyc bone marrow plasma cells after VRD treatment and T lymphocytes as germline control. There are 14 patients in total
|Illumina NovaSeq 6000||10|